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intracranial hypertension
Yasmeen Mulla1, Keira A Markey1, Rebecca L Woolley2, Smitaa Patel2, Susan P Mollan3 and Alexandra J Sinclair1*Abstract
Background: The effect of idiopathic intracranial hypertension (IIH) on quality of life (QOL) is poorly understood.
Our objectives were to compare QOL in IIH to the normal UK population; to investigate QOL changes with
treatment of IIH, using a weight loss intervention, and to determine which clinical factors influence QOL.
Methods: This was a prospective cohort evaluation of QOL, using the 36-Item Short Form (SF-36) Health Survey
questionnaire, before and after a therapeutic dietary intervention which resulted in significant reduction in body
mass index (BMI), intracranial pressure (ICP), papilloedema, visual acuity, perimetric mean deviation (Humphrey
24–2) and headache (six-item headache impact test (HIT-6) and headache diary). Baseline QOL was compared to
an age and gender matched population. The relationship between each clinical outcome and change in QOL
was evaluated.
Results: At baseline, QOL was significantly lower in IIH compared to an age and gender matched population in
most domains, p < 0.001. Therapeutic weight loss led to a significant improvement in 10 out of 11 QOL domains in
conjunction with the previously published data demonstrating significant improvement in papilloedema, visual acuity,
perimetry and headache (p < 0.001) and large effect size. Despite significant improvement in clinical measures only
headache correlated significantly (p < 0.001) with improving QOL domains.
Conclusions: QOL in IIH patients is significantly reduced. It improved with weight loss alongside significant
improvement in clinical measures and headache. However, headache was the only clinical outcome that
correlated with enhanced QOL. Effective headache management is required to improve QOL in IIH.
Keywords: Idiopathic intracranial hypertension; Headache; Quality of life; SF-36Background
Idiopathic intracranial hypertension (IIH), also known
as primary pseudotumour cerebri and previously
benign intracranial hypertension, is characterised by
increased intracranial pressure (ICP) and papilloedema
in the setting of brain imaging with no evidence of
space occupying lesion or venous thrombosis [1,2]. The
condition commonly affects young, obese women (inci-
dence in obese female population 11-21/100,000/year)
and causes headaches and visual loss [3-5]. To date
clinical and research outcomes have focussed on vision
and to a lesser extent headache. The previously re-
ported rates of visual loss (25% permanent severe* Correspondence: a.b.sinclair@bham.ac.uk
1Neurosciences, School of Clinical and Experimental Medicine, College of
Medical and Dental Sciences, University of Birmingham, Vincent Drive,
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Attribution License (http://creativecommons.or
in any medium, provided the original work is pblindness) are likely to be an overestimate, particularly
in specialist centres: yet many IIH patients remain very
disabled by the condition [6,7].
There is a paucity of the literature evaluating QOL in
IIH with currently only three previous published stud-
ies [8-10]. QOL in IIH is not different compared to an
age, gender and BMI matched population in the
domains of vitality, mental health and role limitation
due to emotional problems, implying there are factors
besides obesity in determining QOL in IIH [8]. QOL
has been shown to improve following treatment with
acetazolamide, however it was unclear which factors
contributed to the improvement in QOL [10]. QOL in
IIH has also been shown to be impaired compared to
other neuro-ophthalmic disorders [9].
Our objective was to characterise QOL in an adult IIH
cohort in the United Kingdom and compare it to an ageOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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to assess QOL in the cohort following a therapeutic diet-
ary intervention. QOL parameters were compared to clin-
ical outcome measures to evaluate which factors were
associated with positive changes in QOL.
Methods
Evaluations were conducted alongside a previously re-
ported prospective multicentre cohort study which doc-
uments the full protocol [11]. In summary, twenty five
females with IIH, over the age of 16 years, consented to
participate in the study. IIH was diagnosed in accord-
ance with the updated modified Dandy Criteria [2]. All
participants had a disease duration of 3 months and
signs of active disease with raised ICP pressure >25
cmCSF and papilloedema. Magnetic resonance imaging
and venography did not reveal alternative pathology in
all those recruited.
Study design
The study was a prospective cohort evaluation consisting
of two stages each lasting 3 months with a follow up visit
at 9 months: Stage 1 (0–3 months): no intervention and
Stage 2 (3–6 months): low calorie diet. The intervention
period involved each woman receiving a nutritionally
complete low calorie liquid replacement diet (Lipotrim,
Howard Foundation, Cambridge) of 425 kcal/day.
Subjects were evaluated at baseline, 3 months, 6 months
and a follow up visit at 9 months. The primary outcome
measure was quality of life, using the validated 36-Item
Short Form Health Survey questionnaire (version 1)
[12-14]. This survey consists of 36 questions which evalu-
ate eight dimensions of health: physical functioning, role
limitation due to physical problems, role limitation due to
emotional problems, social functioning, mental health,
energy/vitality, pain and general health perception [12]. A
physical component score and a mental component score
can be calculated in order to summarise the health dimen-
sions [14]. There is a further question asking patients
about their change in health (not included for normative
data). The scoring scale is from 0 (worst QOL) to 100
(best QOL) [14] Other clinical measures were evaluated as
previously described [11]. Assessment of visual function
was carried out using a LogMAR (log of the minimum
angle of resolution) chart to assess visual acuity and auto-
mated perimetry (Humphrey 24–2 central threshold) to
measure the visual field mean deviation. Papilloedema was
evaluated using ocular coherence tomography (OCT)
(Stratus OCTTM V4.0.1, Carl Zeiss, Meditec, Welwyn
Garden City, UK), average retinal nerve fibre layer thick-
ness. A daily headache diary, completed in the week prior
to each visit, evaluated headache severity using a visual
analogue pain scale (VAS), headache frequency (days/
week) and use of analgesia (days/week). A headachequestionnaire (Headache Impact test (HIT-6) score range
36–78) was also completed. ICP was measured by lumbar
puncture by the same physician (AJS) at baseline, 3 and 6
months after all listed outcome measures had been
assessed. Measurements were taken with the patient
breathing steadily in the left lateral position, legs extended
greater than 90° at the hip, allowing adequate time to
ensure a stable ICP reading.
Data and statistical analysis
The statistical analyses were performed using the statis-
tical package SAS version 9.2 (Cary, NC, USA), Stata
version 13 (Statacorp, Texas, USA) and GraphPad Prism
version 5. Missing data were excluded from analyses.
We used two-tailed p values with p < 0.05 considered
statistically significant. We have not adjusted for mul-
tiple testing due to the fact that the SF-36 domains are
not independent of one another, indeed the component
scores are calculated based on the domain scores. This
reduces the probability of us finding a significant domain
by chance. We have, however, additionally stated in the
tables the threshold p values following a Bonferroni cor-
rection to adjust for the multiple tests for the readers
interest. For longitudinal evaluation, the magnitude of
change from baseline to the end of the intervention was
addressed with a measure of effect size. Comparison SF-
36 data was obtained from published normative data in
the United Kingdom (The Oxford Health and Lifestyles
Survey 1991–1992) [15]. The data was matched for gen-
der and we used a linear regression model, adjusting for
age, to compare the normal population data with the
trial data. QOL changes with therapeutic diet were com-
pared at baseline and 3 months; and 3 months and 6
months: these were analysed using paired t-tests. We
correlated the changes in QOL with clinical measures
and obtained Pearson’s coefficient to ascertain a linear
relationship.
Statement of ethical approval and consent
This study was approved by the Dudley local research
ethics committee [06/Q2702/64] and informed written
consent was given by all participants.
Results
25 women entered the study and 20 completed the study.
Figure 1 details numbers of individuals and reasons for
non-participation at each stage of the study. Our study in-
cluded females only and had an age range of 19–54 years
Baseline characteristics are shown in Table 1.
Quality of life in idiopathic intracranial hypertension
At baseline, mean 36-Item Short Form Survey scores
were significantly lower in IIH patients (n=24) in 9 of
the 10 domains compared to normative data (a gender
Figure 1 Study design flowchart.
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The IIH SF-36 summary scores were compared. The
mean difference of IIH versus a matched age and gender
UK population for physical component score was 10.6
(95% CI: 6.7 to 14.5), p < 0.001, but the mean difference
for IIH versus a matched age and gender UK population
for mental component score was not significant. 4.8
(95% CI: 0.3 to 9.3), p=0.036.
Quality of life changes with therapeutic diet
The mean differences in scores were evaluated from the
beginning to the end of each stage. Our previously pub-
lished data demonstrates that there was no significant
improvement over the observation period (stage 1) but
following the diet (stage 2) there was significant im-
provement in weight, BMI, ICP, papilloedema, visual
acuity, headache disability (HIT-6) as well as headache
severity and frequency (Table 2). Analgesic use also sig-
nificantly reduced (p=0.007). Weight, BMI, ICP and
HIT-6 showed a particularly large magnitude of change,
with effect sizes greater than 0.80.
The 36-Item Short Form Health Survey domains did
not improve significantly during stage 1 (no interven-
tion), except for pain (mean change 14.4, p=0.025) andTable 1 Baseline demographics
Mean (SD)
Age in years 34.4 (9.2)
Duration of disease in months 39.0 (49.2)
Weight (kg) 101.5 (16.0)
Body Mass Index (kg/m2) 38.2 (5.0)
Intracranial pressure (cm CSF) 39.8 (5.1)
Number (%)
Taking acetazolamide 11 (44)
Ethnicity
-White 20 (80)
-African-Caribbean 3 (12)
-South West Asian (Indo-Pakistani) 2 (8)energy/vitality (mean change 10.2, p=0.020). Following
therapeutic weight loss (stage 2, low energy diet) the
mean differences in 36-Item Short Form Health Survey
scores during stage 2 improved significantly in 10 of 11
domains (Additional file 1). The magnitude of change
was particularly large (ES ≥ 0.80) for 5 out of the 11
domains: energy/vitality, pain, general health perception,
change in health and physical component score.
We found that there were no significant changes in
quality of life 3 months after the dietary intervention
had finished, suggesting that the improvement in quality
of life was sustained in this period. The change in SF-36
domains do not differ between those who use and do
not use acetazolamide (Diamox) for any of the domains.
Relationship between quality of life and clinical outcomes
The linear relationship between the changes in clinical
outcomes measures and changes 36-Item Short Form
Health Survey domains following the dietary intervention,
were then assessed. Despite the significant improvement
in visual function, reduction in ICP, papilloedema, BMI
and reduction in weight during the dietary intervention,
none of these measures correlated with the improvement
in QOL scores (Additional file 2).
Interestingly the 36-Item Short Form Health Survey
correlated strongly with an improvement in headaches
outcomes: Headache Impact Test scores (HIT-6) corre-
lated significantly with all domains of the 36-Item Short
Form Health Survey (Additional file 3). In particular, the
mental health component score, summarising mental
health dimensions (r=-0.88, p < 0.001), the social function-
ing domain (r=-0.81, p < 0.001) and the energy/vitality
domain (r=-0.79, p < 0.001). Headache severity correlated
significantly with 10 out of 11 domains, particularly role
limitation due to emotional problems (r=-0.78, p < 0.001),
mental component score role (r=-0.73, p=0.002) and
limitation due to physical problems (r=-0.71, p=0.002)
(Table 3). Headache frequency correlated with an im-
provement in Short Form Health Survey scores which was
significant for only 5 out of the 11 domains (p < 0.05) and
the correlation was weaker than headache disability (HIT-
6) and headache severity (Table 3).
Discussion
This study shows that IIH compromises quality of life
which significantly recovers after a therapeutic diet. Im-
proving QOL in IIH is associated with resolving head-
ache but there’s no evidence that it is associated with
improvement in other clinical measures (vision, intracra-
nial pressure and BMI). Patients and physicians may
undervalue or may not be aware of the broad impact of
IIH on health related quality of life. This study expands
our knowledge of the quantitative adverse effects on
patients and determines what factors can improve QOL
Figure 2 Mean short-form survey scores for IIH (baseline) and UK age matched females. P-values for the difference in means are show, *indicates
p < 0.05, **indicates p < 0.01 and ***indicates p < 0.001.
Table 2 Clinical Outcomes and Quality of Life means (SD) at 0 months (baseline), 3 months and 6 months in Idiopathic
intracranial hypertension
0 months (baseline) 3 months 6 months
Mean (SD) Mean (SD) Mean (SD) P-value Effect size
Clinical outcomes
Weight (kg) 101.5 (16.0) 102.5 (16.8) 86.8 (15.6) <0.001 0.92
BMI 38.2 (5.0) 38.6 (5.3) 32.6 (4.7) <0.001 1.12
Intracranial pressure (cm H2O) 39.8 (5.1) 38.0 (5.0) 30.0 (4.9) <0.001 1.92
Headache disability (HIT-6) 57.5 (9.0) 54.5 (1.0) 46.9 (10.1) 0.004 1.18
Headache severity (VAS) 3.8 (2.4) 4.2 (2.8) 1.9 (2.8) 0.015 0.79
Headache frequency (days/week) 3.8 (2.9) 4.4 (2.9) 2.1 (2.8) 0.011 0.59
Papilloedema (OCT) 144.1 (45.5) 135.0 (48.0) 109.3 (27.9) 0.001 0.76
Visual acuity (LogMar) -0.02 (0.10) 0.01 (0.11) -0.06 (0.09) <0.001 0.40
Analgesic use (days/week) 2.2 (2.7) 2.2 (2.5) 0.2 (0.4) 0.007 0.74
Quality of life (SF-36)
Physical functioning 77.3 (22.9) 79.8 (21.2) 87.6 (19.4) <0.001 -0.45
Role limitation due to physical problems 70.6 (29.3) 78.1 (24.7) 91.4 (16.9) <0.001 -0.71
Role limitation due to emotional problems 78.8 (30.0) 76.0 (28.8) 90.1 (18.7) 0.018 -0.38
Social functioning 66.7 (30.3) 78.1 (19.6) 86.9 (22.8) 0.081 -0.67
Mental health 63.2 (22.4) 67.2 (20.5) 74.6 (21.3) 0.048 -0.51
Energy/Vitality 39.4 (20.8) 49.6 (14.4) 71.0 (23.4) <0.001 -1.52
Pain 53.2 (20.2) 67.6 (26.8) 85.2 (16.2) 0.001 -1.58
General health perception 53.1 (18.8) 53.7 (18.6) 72.1 (12.7) 0.001 -1.01
Change in health 52.1 (19.4) 60.4 (19.4) 88.1 (17.0) <0.001 -1.86
Physical component score 40.4 (10.3) 44.1 (10.5) 50.7 (7.4) <0.001 -1.00
Mental component score 45.2 (12.7) 47.1 (9.8) 52.(10.4) 0.020 -0.54
Number 24 24 20
HIT-6, Six-item Headache Impact Test; OCT, Optical Coherence Tomography. VAS, Visual Analogue Score; LogMar, Logarithm of the Minimum Angle of Resolution.
The quality of life scale ranges from 0 (worst quality of life) to 100 (best quality of life). There were no significant differences between 0 and 3 months (no diet),
except for pain (p=0.025) and energy/vitality (p=0.020). P values in the table indicate changes from 3 to 6 months (following diet). If a Bonferroni correction were
applied the p value is reduced to p < 0.0026, but this might represent an overcorrection. Effect size (ES) in the final column indicates the magnitude of change:
ES=0.30 indicates mild/low change, ES=0.50 indicates moderate change and ES ≥ 0.80 indicates large change.
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Table 3 Correlation between changes in the 36-item short form health survey domains and changes in headache disability,
severity and frequency following the therapeutic diet
Domain Headache disability
(Headache impact test-6 score)
Headache severity
(Visual analogue pain scale)
Headache frequency
(days/week)
Physical functioning -0.67 -0.74 -0.48
p=0.001 p=0.001 p=0.052
Role limitation due to physical problems -0.70 -0.71 -0.53
p < 0.001 p=0.002 p=0.029
Role limitation due to emotional problems -0.71 -0.78 -0.38
p < 0.001 p < 0.001 p=0.14
Social functioning -0.81 -0.62 -0.60
p < 0.001 p=0.014 p=0.015
Mental health -0.64 -0.65 -0.46
p=0.003 p=0.009 p=0.075
Energy/Vitality -0.79 -0.70 -0.42
p < 0.001 p=0.004 p=0.11
Pain -0.66 -0.59 -0.60
p=0.002 p=0.018 p=0.010
General health perception -0.67 -0.68 -0.49
p=0.002 p=0.006 p=0.056
Change in health -0.58 -0.39 -0.63
p=0.007 p=0.13 p=0.007
Physical component score -0.59 -0.57 -0.55
p=0.007 p=0.027 p=0.027
Mental component score -0.88 -0.73 -0.45
p < 0.001 p=0.002 p=0.082
If a Bonferroni correction were applied to account for the multiple domains of the SF-36, the p value is reduced to p < 0.0045, but this might represent an
over correction.
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literature [8-10] that compared to the normal population
QOL, as measured by the 36-Item Short Form Health
Survey, QOL in IIH is reduced. This was most notable
in the domains energy/vitality, pain and general health
perception, p < 0.001.
There are characteristics, such as age, gender and obes-
ity, which could potentially contribute to a lower QOL in
IIH, a disease that mainly affects overweight women of
child bearing age. For example females report poorer
health, except in general health perception, p < 0.001 in
UK normative data; there are age differences across the
domain score in UK normative data, such as physical
functioning being as high as 90.1 (16.4) in women aged
18–24, n=780 and as low as 84.8 (18.3), n=917 in women
aged 45–54 [15]. Obesity is associated with a decrease in
physical QOL in a dose–response relationship, while mor-
bid obesity (Body Mass Index >40 kg/m2) has been shown
to have significantly decreased mental QOL when assessed
with 36-Item Short Form Health Survey compared to nor-
mal population results [9]. Surprisingly, our results dem-
onstrate that significant weight loss was not associatedwith improved QOL. The lack of association between
obesity and QOL in IIH has been demonstrated in a study
which compared IIH to a healthy age-and weight- controls
and found lower scores, suggesting that obesity alone can-
not explain the lower QOL in IIH [8].
In this interventional study the measurable clinical
parameters of vision, perimetry, papilloedema and intra-
cranial pressure significantly improved; yet not one of
these variables were significantly associated with en-
hanced QOL. We have, however, demonstrated a mark-
edly significant relationship between positive QOL score
and resolving headache. Our findings agree with earlier
literature showing that headache severity correlates with
quality of life, rather than headache frequency [16]. This
potentially suggests that treatments to modifying head-
ache severity are more important than altering headache
frequency when treating IIH patients to improve QOL .
Of additional interest was the more robust relationship
between improving headache severity and QOL com-
pared to improving headache frequency and QOL.
Headache frequency is frequently regarded in the litera-
ture as the most important outcome measure in trials,
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which most affects quality of life. Of note, headache se-
verity maybe more important that headache frequency
in determining physical function, role limitation due to
emotional problems, mental health, energy and vitality
and general health perception and mental component
score. Unsurprisingly, a reduction in analgesia use (days/
week) correlated with an improvement in quality of life,
particularly the pain domain. We evaluated, acetazolamide
use, and found there to be no significant difference in
QOL for those taking and not taking acetazolamide.
Health-related QOL outcomes are important in decid-
ing whether an intervention is worth adopting [17,18]. A
therapeutic weight loss intervention has already been
shown to reduce intracranial hypertension, improve head-
aches, visual function and reduce papilloedema IIH [11].
Our study demonstrates that health-related QOL signifi-
cant improves following a therapeutic diet, supporting its
use as a suitable treatment for IIH.
There are a number of limitations to this study. Par-
ticipant numbers included in this study were small, with
25 patients included at baseline and 20 patients complet-
ing all stages. This reduces our power to detect differ-
ences if they truly exist. We also accept that multiple
comparisons were made due to the multiple components
of the SF-36 score and clinical measures and accept that
5% of the results could have occurred by chance due to
type 1 error. However, the vast majority of the correla-
tions indicated a significant result with r values substan-
tially different from zero which supports the results.
Ideally, further studies are required looking at QOL
longitudinally with weight loss interventions. Over the
initial control stage, there was little significant change in
the 36-Item Short Form Health Survey scores, except for
energy/vitality and pain. These changes may reflect the
positive psychological effect of entering into a research
study [19]. Furthermore, some QOL domain measures
may require extended periods of time before significant
changes are observed. As this study was relatively short
these potential differences may have been overlooked.
Mental health, in particular, may require a longer period
of observation to detect improvements compared to
quicker resolving factors such as pain. AJS is currently
developing the first national IIH database in the United
Kingdom to enable longitudinal analysis. We did not
evaluate co-morbid depression in our cohort but this
would certain be of interest in future studies.
Modern studies are now reporting a lower incidence
of blindness in IIH (1–3%), compared to previous stud-
ies 6–25% [1,6]. This may be due to increased recogni-
tion of the potentially blinding consequences of IIH in
additional to improved management and monitoring of
visual symptoms [1,6]. This is the first study to report
the relationship between QOL and clinical outcomes.Conclusions
We have established that QOL significantly recovers
after a therapeutic diet. Finally we have shown that
improving QOL in IIH is associated with resolving head-
ache and not with other clinical measures (vision, intra-
cranial pressure and BMI). The management of IIH has
typically focused on the visual parameters because of the
risk of blindness, whilst active treatment of headache is
frequently neglected [1,6]. This study highlights the im-
portance of headache in determining QOL in IIH. We
therefore recommend that specific headache treatment
is key to improving QOL in IIH.
Additional files
Additional file 1: Displays the mean changes in Short-Form Survey
score over the observation period (stage 1) and therapeutic diet
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Additional file 2: Details the correlation between 36-Item Short
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ICP, papilloedema, BMI and weight).
Additional file 3: Displays the correlation between changes in HIT-6
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Survey domains (y axis) during therapeutic diet (stage 2).
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